Metagenomi Therapeutics Long Term Debt 2022-2025 | MGX
Metagenomi Therapeutics long term debt from 2022 to 2025. Long term debt can be defined as the sum of all long term debt fields.
|
Metagenomi Therapeutics Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | $30 |
|
Metagenomi Therapeutics Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2025-09-30 | |
| 2025-06-30 | |
| 2025-03-31 | |
| 2024-12-31 | |
| 2024-09-30 | |
| 2024-06-30 | |
| 2024-03-31 | |
| 2023-12-31 | |
| 2023-09-30 | |
| 2023-06-30 | |
| 2023-03-31 | |
| 2022-12-31 | |
| 2021-12-31 | $30 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.054B | $0.052B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $40.098B | 12.44 |
| BridgeBio Pharma (BBIO) | United States | $14.490B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.689B | 18.18 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.814B | 23.04 |
| Bausch Health Cos (BHC) | Canada | $2.099B | 1.49 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.315B | 9.47 |
| Taysha Gene Therapies (TSHA) | United States | $1.244B | 0.00 |
| Personalis (PSNL) | United States | $0.738B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.428B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.184B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |